Elacestrant (ELA) vs Standard of Care (SOC) in ER+/HER2-- Advanced (adv) or Metastatic Breast Cancer (mBC) With ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial.

Autor:	Bardia, Aditya, O'Shaughnessy, Joyce, Bidard, Francois-Clement, Aftimos, Phillipe, Cortes, Javier, Lu, Janice, Tonini, Giulia, Thea, Kathy Puyana, Paoli, Alessandro, Kaklamani, Virginia
Předmět:	THERAPEUTIC use of antineoplastic agents HORMONE receptor positive breast cancer TUMOR markers TREATMENT effectiveness CONFERENCES & conventions ESTROGEN receptors METASTASIS ESTROGEN antagonists GENETIC mutation
Zdroj:	Journal of Oncology Navigation & Survivorship; Oct2024, Vol. 15 Issue 10, p310-311, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu